Business Wire

MA-EXAGRID

30.11.2021 14:02:10 CET | Business Wire | Press release

Share
ExaGrid Wins 3 Awards at 12th Annual SDC Awards

ExaGrid ®, the industry’s only Tiered Backup Storage solution, today announced that the company was honored with three awards at the 12th annual SDC Awards ceremony, Angel Business Communications’ premier IT awards – the Storage, Digitalisation + Cloud Awards, held in London on November 24, 2021. These new award wins add to ExaGrid’s previous six wins this past fall, totaling nine industry awards in 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005225/en/

ExaGrid’s Reseller Partner Program has been voted “Vendor Channel Program of the Year” for a second year in a row. In 2021, ExaGrid rolled out an optional Solutions Architects certification at no charge to become an ExaGrid Certified Engineer. ExaGrid works with resellers and distributors worldwide. The ExaGrid programs are designed to be easy for partners, with support from the ExaGrid sales team and without milestone commitments. ExaGrid is known for having a Tiered Backup Storage system that ‘just works’ and provides its customers with stellar customer support from an assigned level 2 engineer, ensuring that partners’ customers are well taken care of.

ExaGrid Tiered Backup Storage has been voted “Storage Hardware Innovation of the Year” for a second year in a row. In January of 2021, ExaGrid announced a new line of appliances, including the EX84, its largest appliance to date. The largest configuration, made up of 32 EX84 appliances in a single scale-out system, allows for a full backup of up to 2.7PB with a single deduplicated repository, which is 50% larger than any other system on the market. The net is that ExaGrid offers fast backups, fast restores, a fixed-length backup window as data grows due to its scale-out architecture, ransomware recovery of encrypted primary data, and a system that scales to 50% greater capacity than any other solution in the industry.

ExaGrid Tiered Backup Storage has been voted “Storage Company of the Year” for a second year in a row. In 2021, ExaGrid expanded its product line with greater scalability up to 2.7PB full backup to a single system and well as reduced data center footprint by 30%. ExaGrid has advanced it tools and calculators to further assist customer in calculating the true cost of backup storage up front and over time. These tools show customers what their costs of backup storage will be inclusive of backup retention, yearly data growth, and storage for second site disaster recovery. ExaGrid has had back-to-back record quarters in 2021, and has expanded its customer base to over 3,100 customers in 50 countries. ExaGrid is the only company that is completely dedicated to backup storage, with a goal to solve the issues commonly experienced with backup solutions while providing the best value to its customers.

“We are so honored to win these three awards for a second year in a row, as they each speak to our company’s strengths – an innovative backup storage architecture, a customer-focused approach with high-quality support, and a strong channel program,” said Bill Andrews, President and CEO of ExaGrid. “Congratulations to all of this year’s winners! These awards are decided on by public vote so it means so much to us, and we are so thankful to everyone who voted, and to all of our partners, customers, and staff for their support.”

ExaGrid continues to gain recognition for its Tiered Backup Storage appliances, winning 9 awards in the fall of 2021, including:

  • Storage Awards “The Storries XVIII” - Enterprise Backup Hardware Vendor of the Year
  • Storage Awards “The Storries XVIII” - Immutable Storage Company of the Year
  • Network Computing Awards - Company of the Year
  • Network Computing Awards - Bench Tested Product of the Year
  • Network Computing Awards - Storage Product of the Year
  • Network Computing Awards - The Return on Investment award
  • SDC Awards - Vendor Channel Program of the Year
  • SDC Awards - Storage Hardware Innovation of the Year
  • SDC Awards - Storage Company of the Year

ExaGrid Tiered Backup Storage – Built for Backup

ExaGrid provides Tiered Backup Storage with a front-end disk-cache Landing Zone, the Performance Tier, which writes data directly to disk for the fastest backups, and restores directly from disk for the fastest restores and VM boots. The long-term retention data is tiered to a deduplicated data repository, the Retention Tier, to reduce the amount of retention storage and resulting cost. This two-tiered approach provides the fastest backup and restore performance with lowest cost storage efficiency.

In addition, ExaGrid provides a scale-out architecture where appliances are simply added as data grows. Each appliance includes processor, memory and network ports, so as data grows, all resources required are available to maintain a fixed-length backup window. This scale-out storage approach eliminates expensive forklift upgrades, and allows for mixing appliances of different sizes and models in the same scale-out system, which eliminates product obsolescence while protecting IT investments up front and over time.

About ExaGrid

ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier, delayed deletes, and immutable objects to recover from ransomware attacks. Visit us at exagrid.com or connect with us on LinkedIn . See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup in our customer success stories .

ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye